Free Trial

Intellia Therapeutics' (NTLA) Buy Rating Reiterated at HC Wainwright

Intellia Therapeutics logo with Medical background

HC Wainwright reissued their buy rating on shares of Intellia Therapeutics (NASDAQ:NTLA - Free Report) in a research note issued to investors on Monday,Benzinga reports. The brokerage currently has a $30.00 price target on the stock.

NTLA has been the subject of a number of other research reports. Chardan Capital reiterated a "buy" rating and issued a $68.00 target price on shares of Intellia Therapeutics in a research note on Friday, May 9th. The Goldman Sachs Group restated a "sell" rating and set a $9.00 price objective on shares of Intellia Therapeutics in a research note on Friday, February 28th. Wells Fargo & Company lowered their price objective on Intellia Therapeutics from $60.00 to $50.00 and set an "overweight" rating for the company in a research note on Friday, February 28th. Guggenheim lowered their price objective on Intellia Therapeutics from $55.00 to $45.00 and set a "buy" rating for the company in a research note on Monday, May 12th. Finally, Truist Financial reduced their target price on Intellia Therapeutics from $90.00 to $50.00 and set a "buy" rating on the stock in a report on Tuesday, March 4th. Two analysts have rated the stock with a sell rating, six have given a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, Intellia Therapeutics presently has a consensus rating of "Moderate Buy" and an average price target of $34.95.

Check Out Our Latest Stock Analysis on NTLA

Intellia Therapeutics Trading Up 0.2%

Shares of NASDAQ:NTLA traded up $0.02 on Monday, hitting $9.60. The company had a trading volume of 5,758,175 shares, compared to its average volume of 2,883,590. Intellia Therapeutics has a 52-week low of $5.90 and a 52-week high of $28.18. The business has a 50 day moving average of $8.24 and a 200 day moving average of $9.74. The company has a market cap of $994.37 million, a PE ratio of -1.84 and a beta of 2.14.

Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The company reported ($1.10) EPS for the quarter, topping the consensus estimate of ($1.26) by $0.16. The company had revenue of $16.63 million during the quarter, compared to analyst estimates of $11.39 million. Intellia Therapeutics had a negative return on equity of 56.06% and a negative net margin of 1,154.10%. The firm's revenue was down 42.6% on a year-over-year basis. During the same period in the prior year, the firm posted ($1.12) earnings per share. As a group, equities analysts predict that Intellia Therapeutics will post -5.07 EPS for the current year.

Hedge Funds Weigh In On Intellia Therapeutics

Hedge funds have recently modified their holdings of the stock. GF Fund Management CO. LTD. acquired a new stake in shares of Intellia Therapeutics in the fourth quarter worth $25,000. Sterling Capital Management LLC boosted its position in shares of Intellia Therapeutics by 866.2% in the fourth quarter. Sterling Capital Management LLC now owns 3,198 shares of the company's stock worth $37,000 after buying an additional 2,867 shares during the period. Whipplewood Advisors LLC acquired a new stake in shares of Intellia Therapeutics in the fourth quarter worth $40,000. Resona Asset Management Co. Ltd. acquired a new stake in shares of Intellia Therapeutics in the fourth quarter worth $43,000. Finally, Jones Financial Companies Lllp boosted its position in shares of Intellia Therapeutics by 140.9% in the fourth quarter. Jones Financial Companies Lllp now owns 3,898 shares of the company's stock worth $45,000 after buying an additional 2,280 shares during the period. 88.77% of the stock is currently owned by institutional investors and hedge funds.

Intellia Therapeutics Company Profile

(Get Free Report)

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.

Featured Stories

Analyst Recommendations for Intellia Therapeutics (NASDAQ:NTLA)

Should You Invest $1,000 in Intellia Therapeutics Right Now?

Before you consider Intellia Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Intellia Therapeutics wasn't on the list.

While Intellia Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 Made in America Stocks Under $20 You Need to See!
3 Cheap Growth Stocks Set to Explode This Summer
The Next NVIDIA? Quantum Computing Stocks Set for Explosive Growth

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines